CDTX vs MET · rev $1.3M vs P/E 13, $52.16B cap
Cidara Therapeutics Inc (CDTX) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
MET does not have a complete income-statement cache yet.
CDTX currently screens at market cap $6.96B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the CDTX and MET stock pages for the full models.
Not investment advice.